An official website of the United States government
Home
Name
Tretinoin
Alternate Names
Aberel
Airol
All-trans-retinoic acid
Avita
Dermairol
Eudyna
Renova
Retin-A
Retinoic acid
Retisol-A
Stieva-A
Vesanoid
Vitamin A Acid
Vitinoin
Abbreviations
ATRA
Vit A
Category
Differentiation inducing agent
Subcategory
None
NSC Number
122758
Primary Site
Histology
None
Remarks
Tretinoin is FDA approved for treatment of acute promyelocytic leukemia (APL). It is a retinoid/differentiation agent and at this time the precise mechanism of action has not been fully elucidated so it cannot be assigned to chemotherapy, hormone or BRM/immunotherapy. Code this agent as treatment in the "Other Therapy" data field (using code 1).
Phase II (head & neck)
Administered topically, tretinoin stimulates epithelial turnover and reduces epithelial cell cohesiveness. Under investigation for treatment of Kaposi sarcoma lesions. FDA approved therapy of acute promyelocytic leukemia. NCI.Code this agent as treatment in the "Other Therapy" data field (using code 1).
Phase II (head & neck)
Administered topically, tretinoin stimulates epithelial turnover and reduces epithelial cell cohesiveness. Under investigation for treatment of Kaposi sarcoma lesions. FDA approved therapy of acute promyelocytic leukemia. NCI.Code this agent as treatment in the "Other Therapy" data field (using code 1).
Coding
Please see remarks for additional information
